{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T05:10:49Z","timestamp":1739769049556,"version":"3.37.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,16]]},"DOI":"10.7759\/cureus.79119","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T04:14:26Z","timestamp":1739765666000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Efficacy and Safety of Pluvicto in Chemotherapy-Ineligible Nonagenarians: A Descriptive Case Series"],"prefix":"10.7759","author":[{"given":"Jacob","family":"Charron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Maupin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystal","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshad","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"unstructured":"SEER*Explorer. an interactive website for SEER cancer statistics. (2023). https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&ch....","key":"ref2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial","volume":"49","author":"Satapathy S","year":"2022","unstructured":"Satapathy S, Mittal BR, Sood A, et al.. 177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022, 49:1754-64. 10.1007\/s00259-021-05618-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.216820","article-title":"Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy","volume":"60","author":"Barber TW","year":"2019","unstructured":"Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019, 60:955-62. 10.2967\/jnumed.118.216820","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"27","author":"Hofman MS","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al.. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021, 27:797-804. 10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265259","article-title":"Safety and efficacy of [177Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: report on 80 patients over the age of 80 years","volume":"64","author":"Tauber R","year":"2023","unstructured":"Tauber R, Knorr K, Retz M, et al.. Safety and efficacy of [177Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: report on 80 patients over the age of 80 years. J Nucl Med. 2023, 64:1244-51. 10.2967\/jnumed.122.265259","journal-title":"J Nucl Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265414","article-title":"[177Lu]Lu-PSMA-radioligand therapy efficacy outcomes in taxane-na\u00efve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review and metaanalysis","volume":"64","author":"Satapathy S","year":"2023","unstructured":"Satapathy S, Sahoo RK, Bal C. [177Lu]Lu-PSMA-radioligand therapy efficacy outcomes in taxane-na\u00efve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review and metaanalysis. J Nucl Med. 2023, 64:1266-71. 10.2967\/jnumed.123.265414","journal-title":"J Nucl Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher HI","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al.. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016, 34:1402-18. 10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). (2017). Accessed. February 15, 2025: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm.","key":"ref9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02167-y","article-title":"Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients","volume":"22","author":"Feliu J","year":"2020","unstructured":"Feliu J, Heredia-Soto V, Giron\u00e9s R, Jim\u00e9nez-Munarriz B, Salda\u00f1a J, Guill\u00e9n-Ponce C, Molina-Garrido MJ. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol. 2020, 22:457-67. 10.1007\/s12094-019-02167-y","journal-title":"Clin Transl Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor O","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al.. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021, 385:1091-103. 10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02954-7","article-title":"Quality of life in urologic cancer patients: importance of and satisfaction with specific quality of life domains","volume":"31","author":"Leuteritz K","year":"2022","unstructured":"Leuteritz K, Richter D, Mehnert-Theuerkauf A, Stolzenburg JU, Hinz A. Quality of life in urologic cancer patients: importance of and satisfaction with specific quality of life domains. Qual Life Res. 2022, 31:759-67. 10.1007\/s11136-021-02954-7","journal-title":"Qual Life Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge MM","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, et al.. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024, 25:175-83. 10.1016\/S1470-2045(23)00638-1","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111974","article-title":"From despair to hope: first Arabic experience of 177Lu-PSMA and 161Tb-PSMA therapy for metastatic castration-resistant prostate cancer","volume":"16","author":"Al-Ibraheem A","year":"2024","unstructured":"Al-Ibraheem A, Abdlkadir AS, Sweedat DA, et al.. From despair to hope: first Arabic experience of 177Lu-PSMA and 161Tb-PSMA therapy for metastatic castration-resistant prostate cancer. Cancers (Basel). 2024, 16:1974. 10.3390\/cancers16111974","journal-title":"Cancers (Basel)"},{"unstructured":"Docetaxel injection, solution for intravenous infusion. (2012). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/201525s002lbl.pdf.","key":"ref15"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04612-0","article-title":"225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish F","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, et al.. 225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020, 47:721-8. 10.1007\/s00259-019-04612-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-024-00871-4","article-title":"Dual radionuclide therapy: the synergistic effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in advanced prostate cancer post [177Lu]Lu-PSMA failure","volume":"58","author":"Abdlkadir AS","year":"2024","unstructured":"Abdlkadir AS, Abufara A, Al-Ibraheem A. Dual radionuclide therapy: the synergistic effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in advanced prostate cancer post [177Lu]Lu-PSMA failure. Nucl Med Mol Imaging. 2024, 58:381-2. 10.1007\/s13139-024-00871-4","journal-title":"Nucl Med Mol Imaging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339244-evaluating-the-efficacy-and-safety-of-pluvicto-in-chemotherapy-ineligible-nonagenarians-a-descriptive-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T04:14:34Z","timestamp":1739765674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339244-evaluating-the-efficacy-and-safety-of-pluvicto-in-chemotherapy-ineligible-nonagenarians-a-descriptive-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.79119","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,2,16]]}}}